N/A N=268 Promoting Clinical Guidelines for Opioid Prescribing
Opioid Use
Primary: Average Morphine Milligram Equivalent (MME) Per Day of Chronic Opioid Prescriptions of Clinics — 320.69; 372.33; 275.55; 455.62 average MME/day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=5 Previously Implanted Pudendal Nerve Stimulation
Urinary Retention · Underactive Bladder
Primary: Evoked Bladder Contractions of at Least 20 Centimeters of Water (cmH2O) During Cystometrogram — 1 Participants
Phase 2 N=26 Impact of Evolocumab in Cardiac Transplant Patients With CAV
Heart Transplant
Primary: Percent Change in Serum LDL (mg/dL) After 12 Weeks of Evolocumab — 68 percent change
Phase 1 N=22 A Study Comparing Two Forms of Tafamidis Without Food and the Amount of Tafamidis in the Blood With Food
Healthy
Primary: Pharmacokinetics(PK) Parameter - Area Under the Concentration-time Curve to Infinity (AUCinf) of PF-06291826 — 60670; 67690; 60210 Nanograms * hour per milliliter
Phase 3 N=280 Efficacy of 300 mg Ibuprofen Prolonged-Release Tablets for the Treatment of Pain After Surgical Removal of Impacted Third Molars
Pain
Primary: Summed Pain Intensity Difference Over 0 to 12 Hours (SPID12) After Time 0 — 51.84; 56.33; 19.11 score on a scale*hours — p=<0.0001
Phase 1 N=97 Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
Atopic Dermatitis
Primary: Part 1: SAD Cohorts: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 0; 0; 0; 2 Participants
N/A N=112 Nicotine Withdrawal Symptoms and Smoking Relapse
Nicotine Dependence
Primary: BOLD Activation in Right ACC During Parametric Flanker Task tDCS Stimulation — 1.051567464; 0.867749333; 0.8973946; 1.143702607 Percent BOLD change
Phase 2 N=24 PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Clinically Important Immune-related Adverse Events (for the Lead-In Cohort) — 1; 1; 1; 1 Participants
Phase 2 N=32 Comparison of Metvix Photodynamic Therapy (PDT) With Its Vehicle in the Treatment of Photoaged Skin
Photoaged Skin
Primary: Number of Participants With Severity of Photodamage — 0; 0; 1; 0 Participants
Phase 2 N=216 Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Change in EASI From Baseline to Week 16 — -9.99; -8.83; -8.87; -9.11 score on a scale
N/A N=776 PROmotion of FLU Vaccine Uptake in the Emergency Department - PROFLUVAXED
Influenza Vaccination
Primary: Influenza Vaccine Uptake at 30 Days Comparing Intervention M and Non Intervention — 86; 47 Participants — p=<0.0001
Phase 2 N=23 Cannabidiol for ASD Open Trial
ASD · Autism Spectrum Disorder
Primary: Clinical Global Impression Scale-Improvement (CGI-I) — 3.17; 2.56; 2.25 score on a scale
Early Phase 1 N=8 Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation
AMD
Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…
Phase 3 N=2,232 Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives
Hypertension · Kidney Diseases
Primary: Change in Estimated Glomerular Filtration Rate
N/A N=1,001 Code Blue Outcomes & Process Improvement Through Leadership Optimization Using Teleintensivists-Simulation
Cardiac Arrest
Primary: Fraction of Pulseless Time With no Chest Compressions — 0.22; 0.19 Fraction analysis time CPR not delivered — p=0.41